Why Shares Of AstraZeneca Are Down By 3% Today?The stock has been trending down since mid-July 2020.
AstraZeneca Video 23.03.21.
AstraZeneca Stock Moves Lower As U.S. Health Officials Seek More Data On Its COVID-19 Vaccine
Shares of AstraZeneca found themselves under strong pressure after U.S. health officials criticised trial data that was published on Monday. The main concern of health officials was that the data was outdated.
Trading Derivatives carries a high level of risk to your capital and you should only trade with money you can afford to lose. Trading Derivatives may not be suitable for all investors, so please ensure that you fully understand the risks involved, and seek independent advice if necessary. A Product Disclosure Statement (PDS) can be obtained either from this website or on request from our offices and should be considered before entering into a transaction with us. Raw Spread accounts offer spreads from 0.0 pips with a commission charge of USD $3.50 per 100k traded. Standard account offer spreads from 1 pips with no additional commission charges. Spreads on CFD indices start at 0.4 points. The information on this site is not directed at residents in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.
According to AstraZeneca’s response, its press release used the data avalable through February 17. The company promised to work with U.S. health officials to address their concerns.
Previously, European countries paused the use of AstraZeneca COVID-19 vaccine on concerns about serious side effects which included blood clots. The World Health Organization stated that the benefits of the vaccine outweighted its risks and that it recommended that vaccinations continued. However, it is clear that public confidence in the vaccine has declined. In addition, problems of AstraZeneca vaccine may have hurt confidence in vaccination in general.
What’s Next For AstraZeneca?
AstraZeneca shares have been trending down since July 2020 when the stock reached its high at $64.94 on vaccine enthusiasm. The rollout of the vaccine was followed by various problems, and the latest criticism from U.S. health officials is just another problem for the company.
At current levels, AstraZeneca stock is trading at 15 forward P/E which is not cheap compared to the peer group. The company’s problems with the vaccine add to the pressure as they create negative headlines.
While AstraZeneca is a huge drug manufacturer whose sales are not limited to coronavirus vaccine, investors and traders should not understimate the impact of negative headlines on the price of the company’s shares.
Most likely, the stock will need an upside trend in company’s earnings estimates to move higher. At this point, nobody knows whether revenue from COVID-19 vaccines will be recurring, but AstraZeneca must solve existing problems before the market will start to evaluate the longer-term revenue potential of its coronavirus vaccine.
For a look at all of today’s economic events, check out our economic calendar.